New drug combo aims to shorten tough TB treatment
NCT ID NCT07393438
First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests whether adding acetohydroxamic acid (AHA) to a short-course drug regimen can safely and effectively treat multidrug-resistant tuberculosis (MDR-TB). About 120 adults with confirmed MDR-TB will receive either AHA or a placebo along with standard short-course antibiotics. The main goals are to check safety and find the best dose of AHA, while also measuring how quickly the bacteria clear from sputum.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIDRUG-RESISTANT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Chest Hospital
Hefei, Anhui, 230000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.